Anti-CD19

Chinese Research Reveals Sequential Infusion of Humanized CD19-Modified & CD22-modified CAR-T Cells Aid Relapsed ALL

Mar 26, 2019 | Acute Lymphoblastic Leukemia, Anti- CD22, Anti-CD19, Chimeric Antigen Receptor, China, Humanized, Relapsed

DovePress reports a group of Chinese universities note CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and re-infusion of CAR-T cells is not always...